2018
DOI: 10.1634/theoncologist.2017-0690
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Lessons Learned. The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti‐EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents.Background.Epider… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
12
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(12 citation statements)
references
References 25 publications
(46 reference statements)
0
12
0
Order By: Relevance
“…IL1RL1 inhibits proliferation and metastasis of CRC through modification of the tumor microenvironment 68. EGFL7 is a pro-angiogenic factor in glioblastoma and acute myeloid leukemia 69, 70, and a therapeutic target for ongoing clinical trials 71. Therefore, decoding the function and underlying mechanisms of these AS events may be significant for the development of novel therapeutic strategies.…”
Section: Discussionmentioning
confidence: 99%
“…IL1RL1 inhibits proliferation and metastasis of CRC through modification of the tumor microenvironment 68. EGFL7 is a pro-angiogenic factor in glioblastoma and acute myeloid leukemia 69, 70, and a therapeutic target for ongoing clinical trials 71. Therefore, decoding the function and underlying mechanisms of these AS events may be significant for the development of novel therapeutic strategies.…”
Section: Discussionmentioning
confidence: 99%
“…As results, a total of 37 DEAS events were found to be associated with OS, and 68 DEAS events were found to be associated with DFS ( P < .05, Supplementary Table S6 ). The genes with survival associated AS events, including CD44, CXCL12, EGFL7, IL4R and TCF7, which itself play critical roles in cancer biology [ [54] , [55] , [56] , [57] ]. More importantly, this genome-wide approach provides numerous prognostic AS events which might have an underlying mechanism in CRC initiation or maintenance.…”
Section: Discussionmentioning
confidence: 99%
“…Targeting EGFL7 with the monoclonal antibody parsatuzumab has been tested in a phase II clinical trial. Results showed no improvement with the addition of parsatuzumab to bevacizumab or chemotherapy for metastatic colon cancer (9, 10). Complete understanding of the biological functions of EGF like proteins is critical for development of biomarker-guided targeting of EGF like proteins in cancer treatment.…”
Section: Introductionmentioning
confidence: 99%